A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment ... we’ve been losing the battle to depression with rates of depression nearly doubling ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.